Theriva Biologics Changes Principal Executive Offices

TL;DR

Theriva Biologics moved its HQ to Rockville, MD.

AI Summary

On December 15, 2025, Theriva Biologics, Inc. filed an 8-K report. The filing indicates a change in the company's principal executive offices to 9605 Medical Center Drive, Suite 270, Rockville, Maryland 20850. The company was formerly known as Synthetic Biologics, Inc. and ADEONA PHARMACEUTICALS, INC. prior to that.

Why It Matters

This filing signals a physical relocation for Theriva Biologics, Inc., which could impact operational logistics and potentially investor perception of its growth or restructuring.

Risk Assessment

Risk Level: low — The filing pertains to a change in address, which is a routine administrative event with no immediate financial or operational risk.

Key Players & Entities

• Theriva Biologics, Inc. (company) — Registrant
• Synthetic Biologics, Inc. (company) — Former company name
• ADEONA PHARMACEUTICALS, INC. (company) — Former company name
• 9605 Medical Center Drive, Suite 270, Rockville, Maryland 20850 (location) — New principal executive offices

FAQ

Key Financial Figures

• $0.001 — registered Common stock, par value $0.001 per share TOVX NYSE American Indica

Filing Documents

• tm2533572d1_8k.htm (8-K) — 24KB
• 0001104659-25-121246.txt ( ) — 186KB
• syn-20251215.xsd (EX-101.SCH) — 3KB
• syn-20251215_lab.xml (EX-101.LAB) — 33KB
• syn-20251215_pre.xml (EX-101.PRE) — 22KB
• tm2533572d1_8k_htm.xml (XML) — 4KB

01. Other Events

Item 8.01. Other Events. On December 15, 2025, Theriva Biologics, Inc. (the "Company") called to order its Special Meeting of Stockholders (the "Special Meeting"). At that time, there were not present or represented by proxy a sufficient number of shares of the Company's common stock to constitute a quorum. As a result, the Company was not able to convene the Special Meeting. The Company has determined to call a new special meeting to seek approval of the warrant exercsie proposal and adjournment proposal set forth in the proxy statement filed on November 10, 2025. The Company will announce the date and time of the new special meeting and will subsequently file and mail proxy materials as required. Under that certain warrant inducement agreement (the "Inducement Agreement"), dated October 16, 2025, by and between the Company and certain institutional investors, the Company agreed to use its reasonable best efforts to call a stockholder meeting within 60 days following the closing of the transactions contemplated by the Inducement Agreement for the purpose of seeking approval of the issuance of up to an aggregate of 16,184,560 shares of the Company's common stock upon the exercise of certain common stock purchase warrants ("New Warrants") issued pursuant to the Inducement Agreement ("Stockholder Approval"). The purpose of the Special Meeting was to seek such Stockholder Approval. Because the Company was not able to convene the Special Meeting, the Company will be required under the Inducement Agreement to call an additional meeting of stockholders every 60 days thereafter to seek Stockholder Approval until the earlier of the date on which Stockholder Approval is obtained or the New Warrants are no longer outstanding.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: December 15, 2025 THERIVA BIOLOGICS, INC. By: /s/ Steven A. Shallcross Name: Steven A. Shallcross Title: Chief Executive Officer and Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR